A Phase IIb/III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C, Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TCM 700C (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

28 Apr 2017 Biomarkers information updated
03 Jul 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight